Mylan Stock Price, News & Analysis (NASDAQ:MYL)

$40.52 0.51 (1.27 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close$40.52
Today's Range$39.21 - $40.78
52-Week Range$29.39 - $45.87
Volume11.18 million shs
Average Volume6.36 million shs
Market Capitalization$21.74 billion
P/E Ratio8.62
Dividend YieldN/A
Beta1.38

About Mylan (NASDAQ:MYL)

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MYL
CUSIP62853010
Phone44-0-17-0785-3000

Debt

Debt-to-Equity Ratio1.05%
Current Ratio1.46%
Quick Ratio0.95%

Price-To-Earnings

Trailing P/E Ratio8.62
Forward P/E Ratio8.89
P/E Growth2.22

Sales & Book Value

Annual Sales$11.08 billion
Price / Sales1.96
Cash Flow$7.60 per share
Price / Cash5.33
Book Value$20.78 per share
Price / Book1.95

Profitability

Trailing EPS$1.66
Net Income$480 million
Net Margins7.28%
Return on Equity20.63%
Return on Assets7.19%

Miscellaneous

Employees35,000
Outstanding Shares536,440,000

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) issued its earnings results on Monday, November, 6th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.20 by $0.10. The business had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. Mylan's revenue was down 2.3% on a year-over-year basis. During the same period last year, the business posted $1.38 EPS. View Mylan's Earnings History.

When will Mylan make its next earnings announcement?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Mylan.

What guidance has Mylan issued on next quarter's earnings?

Mylan issued an update on its FY18 earnings guidance on Monday, November, 6th. The company provided EPS guidance of $5.40 for the period, compared to the Thomson Reuters consensus estimate of $5.33. Mylan also updated its FY17 guidance to $4.45-4.70 EPS.

Where is Mylan's stock going? Where will Mylan's stock price be in 2017?

17 equities research analysts have issued 12-month price objectives for Mylan's stock. Their forecasts range from $29.39 to $59.00. On average, they expect Mylan's stock price to reach $42.09 in the next year. View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:

  • 1. According to Zacks Investment Research, "Mylan’s third-quarter results were dismal as the company missed on both earnings and sales estimates due to ongoing challenges in North America. The quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. In a major boost, Mylan received FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. However, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback. The FDA Committee had unanimously recommended the approval of biosimilar version of Herceptin. However, the anticipated FDA goal date set under the Biosimilar User Fee Act was deferred to December from September 2017. Shares have performed better than the industry so far in 2017." (11/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "News outlets today reported State attorney generals are seeking to sue Mylan’s president and executive director, Rajiv Malik, as part of a civil investigation, according to Connecticut Attorney General George Jepsen." (10/31/2017)
  • 3. Argus analysts commented, "junior version" (8/22/2017)
  • 4. Mizuho analysts commented, "We were previously modeling 2017 generic Advair sales of $150M ramping to peak sales of $363M in 2020. Without the 2017 contribution we would still fall generally in line with consensus revenue estimates for 2017 (~$12.7B), which is below the mid-point of the guidance range of $12.25-13.75B. It is unclear if Mylan can get its product to the market before year end so it may be more conservative to exclude it for now, though we continue to anticipate its launch next year. While the limited visibility provided on this product may be frustrating to investors, we think that the magnitude of the stock reaction creates a buying opportunity given the small overall contribution from this generic in the near-term. We therefore reiterate our Buy rating and $53 PT. Next Advair-related event: Hikma/Vectura has a May 10 GDUFA date for their own generic Advair, and Hikma indicated that it will be ready to launch immediately after approval. Unlike Mylan’s product, which is hoped to be an AB-rated generic, but also one with brand recognition, Hikma’s generic will not be marketed under a brand name. Hikma mgmt has indicated that its Advair generic will make up the majority of its $120M new-launch guidance in 2017 (assuming one other competitor in the market)." (3/30/2017)
  • 5. Royal Bank of Canada analysts commented, "MYL reported 4Q today and hosted what we thought was an upbeat 2017 Investor Day showcasing an impressive pipeline. While overall performance remains stable avoiding headwinds felt by smaller peers, 2017 EPS and stock upside will be linked to a few key approvals along with business development. No change to Sector Perform rating but our price target moves up to $48 on higher EPS...First time 2017 guidance was favorable but there are a lot of moving parts to consider. We said going in that an ambitious 2017 outlook wouldn't be enough unless it came with a solid 4Q result. While visibility into specific 4Q drivers was not as high as we would like, it did provide some comfort around MYL's overall stability in a challenging generic environment. The 2017 guidance range of $5.15 to $5.55 captured consensus and helped drive the +7% move in the stock today, but focus will now shift to several important drivers to get there. As we suspected, that range includes risk-adjusted generic Advair, generic Copaxone 20/40mg as well as some incremental business development. Epipen profit impact was quantified and the driver of the slight gross margin moderation. Our new forecasts for 2017-19E move higher and are now $5.30, $5.75 and $6.12 (the $6.00 MYL EPS target in 2018E remains). Based on our new 2018 EBITDA, MYL trades at 9.1x EV/EBITDA - above historical pre-2014 levels." (3/2/2017)

Are investors shorting Mylan?

Mylan saw a decline in short interest in November. As of November 30th, there was short interest totalling 21,122,199 shares, a decline of 12.6% from the November 15th total of 24,179,923 shares. Based on an average daily trading volume, of 5,331,193 shares, the days-to-cover ratio is currently 4.0 days. Approximately 4.2% of the company's stock are short sold.

Who are some of Mylan's key competitors?

Who owns Mylan stock?

Mylan's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Pzena Investment Management LLC (4.24%), Greenlight Capital Inc. (2.00%), Migdal Insurance & Financial Holdings Ltd. (1.18%), Bank of New York Mellon Corp (0.76%), Menora Mivtachim Holdings LTD. (0.69%) and Orbimed Advisors LLC (0.67%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, John D Sheehan, Joseph C Md Maroon, Laboratories Abbott, Mark W Parrish, Melina E Higgins, Rajiv Malik, Robert J Cindrich, Robert J Coury and Wendy Cameron. View Institutional Ownership Trends for Mylan.

Who sold Mylan stock? Who is selling Mylan stock?

Mylan's stock was sold by a variety of institutional investors in the last quarter, including Clal Insurance Enterprises Holdings Ltd, Migdal Insurance & Financial Holdings Ltd., Prudential Financial Inc., Teacher Retirement System of Texas, Parametric Portfolio Associates LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Caisse DE Depot ET Placement DU Quebec and HM Payson & Co.. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Laboratories Abbott and Rajiv Malik. View Insider Buying and Selling for Mylan.

Who bought Mylan stock? Who is buying Mylan stock?

Mylan's stock was purchased by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, Schroder Investment Management Group, Russell Investments Group Ltd., GMT Capital Corp, Assenagon Asset Management S.A., Wells Fargo & Company MN, Point72 Asset Management L.P. and Asset Management One Co. Ltd.. Company insiders that have bought Mylan stock in the last two years include Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich and Wendy Cameron. View Insider Buying and Selling for Mylan.

How do I buy Mylan stock?

Shares of Mylan can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of Mylan stock can currently be purchased for approximately $40.52.

How big of a company is Mylan?

Mylan has a market capitalization of $21.74 billion and generates $11.08 billion in revenue each year. The company earns $480 million in net income (profit) each year or $1.66 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

How can I contact Mylan?

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000.


MarketBeat Community Rating for Mylan (MYL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  571 (Vote Outperform)
Underperform Votes:  398 (Vote Underperform)
Total Votes:  969
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mylan (NASDAQ:MYL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.772.732.712.71
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
13 Buy Rating(s)
2 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
2 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
2 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
2 Strong Buy Rating(s)
Consensus Price Target: $46.16$45.52$45.86$51.28
Price Target Upside: 16.89% upside21.74% upside43.72% upside38.66% upside

Mylan (NASDAQ:MYL) Consensus Price Target History

Price Target History for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017GuggenheimInitiated CoverageBuy -> Buy$59.00LowView Rating Details
11/30/2017Cantor FitzgeraldSet Price TargetHold$34.00MediumView Rating Details
11/7/2017Royal Bank of CanadaBoost Price TargetSector Perform -> Sector Perform$32.00 -> $37.00N/AView Rating Details
10/24/2017MizuhoReiterated RatingBuy$37.00N/AView Rating Details
10/6/2017J P Morgan Chase & CoReiterated RatingOverweight$44.00 -> $48.00N/AView Rating Details
10/6/2017Morgan StanleyBoost Price TargetEqual Weight$36.00 -> $39.00N/AView Rating Details
10/4/2017CitigroupSet Price TargetBuy$42.00N/AView Rating Details
10/5/2017InstinetReiterated RatingBuy$37.00N/AView Rating Details
10/5/2017CowenReiterated RatingMarket Perform$30.00 -> $36.00N/AView Rating Details
10/4/2017Wells Fargo & CompanySet Price TargetHold$30.00 -> $32.00N/AView Rating Details
10/4/2017BTIG ResearchBoost Price TargetBuy -> Buy$42.00 -> $45.00HighView Rating Details
9/29/2017BMO Capital MarketsReiterated RatingBuy$45.00LowView Rating Details
8/22/2017ArgusDowngradeBuy -> Hold$47.59 -> $29.39LowView Rating Details
5/22/2017BarclaysUpgradeEqual Weight -> Overweight$47.00 -> $50.00LowView Rating Details
4/18/2017Deutsche BankLower Price TargetBuy$52.00 -> $51.00LowView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
12/30/2016Stifel NicolausReiterated RatingPositiveN/AView Rating Details
10/10/2016Raymond James FinancialUpgradeMarket Perform -> Strong-Buy$57.00N/AView Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00N/AView Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00N/AView Rating Details
8/25/2016Goldman Sachs GroupReiterated RatingConviction-Buy$60.00N/AView Rating Details
8/24/2016Bank of AmericaReiterated RatingBuy$70.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Mylan (NASDAQ:MYL) Earnings History and Estimates Chart

Earnings by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$1.42N/AView Earnings Details
11/6/2017Q3 2017$1.20$1.10$3.09 billion$2.99 billionViewN/AView Earnings Details
8/9/2017Q2 2017$1.18$1.10$3.00 billion$2.96 billionViewListenView Earnings Details
5/10/2017Q1 17$0.92$0.93$2.81 billion$2.72 billionViewN/AView Earnings Details
3/1/2017Q4 2016$1.42$1.57$3.18 billion$3.27 billionViewN/AView Earnings Details
11/9/2016Q3 2016$1.50$1.38$3.12 billion$3.06 billionViewListenView Earnings Details
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.70$0.70$2.22 billion$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.70$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.63$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Mylan (NASDAQ:MYL) Earnings Estimates

Current Year EPS Consensus Estimate: $4.56 EPS
Next Year EPS Consensus Estimate: $5.28 EPS

Dividends

Dividend History for Mylan (NASDAQ:MYL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mylan (NASDAQ MYL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 75.04%
Insider Trades by Quarter for Mylan (NASDAQ:MYL)
Insider Trades by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Anthony MauroInsiderSell10,000$40.00$400,000.00View SEC Filing  
6/9/2017Rajiv MalikPresidentSell25,000$40.00$1,000,000.00View SEC Filing  
3/23/2017Laboratories AbbottMajor ShareholderSell44,000,000$41.60$1,830,400,000.00View SEC Filing  
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mylan (NASDAQ MYL) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Mylan (MYL) Will Announce Quarterly Sales of $3.28 BillionZacks: Analysts Expect Mylan (MYL) Will Announce Quarterly Sales of $3.28 Billion
www.americanbankingnews.com - December 17 at 4:56 AM
Stock Traders Purchase Large Volume of Call Options on Mylan (MYL)Stock Traders Purchase Large Volume of Call Options on Mylan (MYL)
www.americanbankingnews.com - December 17 at 1:34 AM
Mylan (MYL) and NephroGenex (NRXGQ) Head to Head ReviewMylan (MYL) and NephroGenex (NRXGQ) Head to Head Review
www.americanbankingnews.com - December 16 at 3:26 AM
Head to Head Review: NephroGenex (NRXGQ) & Mylan (MYL)Head to Head Review: NephroGenex (NRXGQ) & Mylan (MYL)
www.americanbankingnews.com - December 15 at 7:10 PM
Mylan (MYL) Receives Consensus Recommendation of "Buy" from AnalystsMylan (MYL) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 15 at 11:42 AM
NephroGenex (NRXGQ) versus Mylan (MYL) Head to Head SurveyNephroGenex (NRXGQ) versus Mylan (MYL) Head to Head Survey
www.americanbankingnews.com - December 15 at 5:30 AM
Mylan (MYL) vs. NephroGenex (NRXGQ) Head to Head SurveyMylan (MYL) vs. NephroGenex (NRXGQ) Head to Head Survey
www.americanbankingnews.com - December 15 at 3:10 AM
Mylan (MYL) Says PTAB Institutes Inter Partes Review Against Sanofis Lantus PatentsMylan (MYL) Says PTAB Institutes Inter Partes Review Against Sanofi's Lantus Patents
www.streetinsider.com - December 14 at 5:28 PM
Mylan LaboratoriesMylan Laboratories
www.marketwatch.com - December 14 at 5:28 PM
BRIEF-Mylan Announces U.S. Regulators Review Proceedings On All Claims Against Sanofis Lantus PatentsBRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents
www.reuters.com - December 14 at 10:06 AM
Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofis Lantus® PatentsMylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus® Patents
www.prnewswire.com - December 14 at 7:52 AM
Mylan (MYL) Short Interest Down 12.6% in NovemberMylan (MYL) Short Interest Down 12.6% in November
www.americanbankingnews.com - December 14 at 4:10 AM
Mylan (MYL) vs. NephroGenex (NRXGQ) Head to Head ComparisonMylan (MYL) vs. NephroGenex (NRXGQ) Head to Head Comparison
www.americanbankingnews.com - December 13 at 5:38 PM
Can Adamis Bleed Mylan Dry?Can Adamis Bleed Mylan Dry?
www.msn.com - December 13 at 5:04 PM
BRIEF-Mylan Says Teva Has Dismissed Its Pending Litigation Against CoBRIEF-Mylan Says Teva Has Dismissed Its Pending Litigation Against Co
www.reuters.com - December 13 at 10:19 AM
Competitor dismisses claims against Mylans generic MS drugCompetitor dismisses claims against Mylan's generic MS drug
www.bizjournals.com - December 13 at 10:19 AM
Stocks making the biggest moves premarket: PEP, MAT, VZ, MYL & moreStocks making the biggest moves premarket: PEP, MAT, VZ, MYL & more
finance.yahoo.com - December 12 at 10:23 AM
Mylan: The Only Specialty Pharma Stock to Buy?Mylan: The Only Specialty Pharma Stock to Buy?
finance.yahoo.com - December 12 at 10:23 AM
Mylan (MYL) Now Covered by GuggenheimMylan (MYL) Now Covered by Guggenheim
www.americanbankingnews.com - December 12 at 8:52 AM
Mylan (MYL) Says Teva (TEVA) Dismissed Litigation After it Won U.S. Court Ruling Related to Tevas Cold Filtration Patents for Copaxone 40 mg/mLMylan (MYL) Says Teva (TEVA) Dismissed Litigation After it Won U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone 40 mg/mL
www.streetinsider.com - December 11 at 5:06 PM
Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Tevas Cold Filtration Patents for Copaxone® 40 mg/mLTeva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/mL
www.prnewswire.com - December 11 at 12:22 PM
UnitedHealth buys DaVita for $4.9BUnitedHealth buys DaVita for $4.9B
finance.yahoo.com - December 8 at 4:49 PM
Financial Survey: Mylan (MYL) vs. NephroGenex (NRXGQ)Financial Survey: Mylan (MYL) vs. NephroGenex (NRXGQ)
www.americanbankingnews.com - December 8 at 3:30 PM
Head to Head Analysis: NephroGenex (NRXGQ) vs. Mylan (MYL)Head to Head Analysis: NephroGenex (NRXGQ) vs. Mylan (MYL)
www.americanbankingnews.com - December 8 at 3:26 AM
NephroGenex (NRXGQ) vs. Mylan (MYL) Head to Head ReviewNephroGenex (NRXGQ) vs. Mylan (MYL) Head to Head Review
www.americanbankingnews.com - December 7 at 7:44 PM
Maryland to receive almost $10 million from Mylan over EpiPen chargesMaryland to receive almost $10 million from Mylan over EpiPen charges
finance.yahoo.com - December 7 at 5:14 PM
Head to Head Survey: Mylan (MYL) & NephroGenex (NRXGQ)Head to Head Survey: Mylan (MYL) & NephroGenex (NRXGQ)
www.americanbankingnews.com - December 7 at 5:30 AM
Financial Contrast: Mylan (MYL) versus NephroGenex (NRXGQ)Financial Contrast: Mylan (MYL) versus NephroGenex (NRXGQ)
www.americanbankingnews.com - December 5 at 3:30 PM
Mylan To Commercialize Generic Busulfex Injection In U.S. - Quick FactsMylan To Commercialize Generic Busulfex Injection In U.S. - Quick Facts
www.rttnews.com - December 4 at 4:54 PM
Mylan NV – Value Analysis (NASDAQ:MYL) : December 4, 2017Mylan NV – Value Analysis (NASDAQ:MYL) : December 4, 2017
finance.yahoo.com - December 4 at 4:54 PM
Mylan (MYL) Given a $46.00 Price Target by UBS AnalystsMylan (MYL) Given a $46.00 Price Target by UBS Analysts
www.americanbankingnews.com - December 4 at 10:14 AM
Mylan Up on FDA Approval & Amazons Rumored Pharmacy InterestMylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest
www.zacks.com - December 4 at 9:58 AM
Mylan and Aspen Announce Launch of Generic Busulfex® InjectionMylan and Aspen Announce Launch of Generic Busulfex® Injection
finance.yahoo.com - December 4 at 9:58 AM
Amazon could make your medication a lot cheaperAmazon could make your medication a lot cheaper
finance.yahoo.com - December 3 at 4:54 PM
Mylan (MYL) Stock Rating Upgraded by ValuEngineMylan (MYL) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - December 3 at 12:40 AM
FDA approves Mylans biosimilar of Roches breast cancer treatmentFDA approves Mylan's biosimilar of Roche's breast cancer treatment
finance.yahoo.com - December 1 at 5:16 PM
FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylans Deep Expertise in Developing Complex ProductsFDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan's Deep Expertise in Developing Complex Products
finance.yahoo.com - December 1 at 5:16 PM
Mylan Pops After FDA Approves Its Generic Blood ThinnerMylan Pops After FDA Approves Its Generic Blood Thinner
finance.yahoo.com - December 1 at 5:16 PM
Why Ambarella, Foundation Medicine, and Mylan Jumped TodayWhy Ambarella, Foundation Medicine, and Mylan Jumped Today
finance.yahoo.com - December 1 at 5:16 PM
NephroGenex (NRXGQ) and Mylan (MYL) Critical AnalysisNephroGenex (NRXGQ) and Mylan (MYL) Critical Analysis
www.americanbankingnews.com - November 30 at 7:24 PM
Mylan (MYL) versus NephroGenex (NRXGQ) Head-To-Head AnalysisMylan (MYL) versus NephroGenex (NRXGQ) Head-To-Head Analysis
www.americanbankingnews.com - November 30 at 5:56 PM
When it comes to high drug prices, Big Pharma blames someone elseWhen it comes to high drug prices, Big Pharma blames someone else
finance.yahoo.com - November 30 at 4:53 PM
European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocons Proposed Biosimilars Trastuzumab and PegfilgrastimEuropean Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Trastuzumab and Pegfilgrastim
finance.yahoo.com - November 30 at 4:53 PM
Mylan (MYL) PT Set at $34.00 by Cantor FitzgeraldMylan (MYL) PT Set at $34.00 by Cantor Fitzgerald
www.americanbankingnews.com - November 30 at 2:28 PM
Attention Biotech Investors: Mark Your Calendar For These December PDUFA DatesAttention Biotech Investors: Mark Your Calendar For These December PDUFA Dates
www.msn.com - November 30 at 10:27 AM
Comparing Mylan (MYL) & NephroGenex (NRXGQ)Comparing Mylan (MYL) & NephroGenex (NRXGQ)
www.americanbankingnews.com - November 30 at 5:34 AM
The global insomnia therapeutics market is expected to reach USD 3.45billion by 2025The global insomnia therapeutics market is expected to reach USD 3.45billion by 2025
www.bizjournals.com - November 29 at 10:05 AM
$3.28 Billion in Sales Expected for Mylan N.V. (MYL) This Quarter$3.28 Billion in Sales Expected for Mylan N.V. (MYL) This Quarter
www.americanbankingnews.com - November 29 at 6:50 AM
Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%
finance.yahoo.com - November 28 at 10:16 AM
FDA issues guidance that could make it easier for EpiPen rivals to come to marketFDA issues guidance that could make it easier for EpiPen rivals to come to market
finance.yahoo.com - November 28 at 10:16 AM

SEC Filings

Mylan (NASDAQ:MYL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mylan (NASDAQ:MYL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mylan (NASDAQ MYL) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.